| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2014: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Outline of Final Research Achievements |
Based on high-throughput sequencing using estrogen-sensitive and hormone therapy-refractory model breast cancer cells, we identified several long noncoding RNAs that are transcribed from the vicinity of estrogen receptor binding sites and exhibit estrogen-dependent expression. We found that the siRNA-mediated knockdown of these noncoding RNAs inhibited the growth of breast cancer cells including hormone therapy-refractory types and the growth of breast cancer cell-derived tumors inoculated in nude mice. Based on functional screenings, we identified several relevant factors and microRNAs together with their target genes, which have associations with prognosis of breast cancer patients. Those molecules could be clinically applied to diagnostic and therapeutic targets for breast cancer management.
|
